Pharmaceuticals
Opioid Analgesics Market

Opioid Analgesics Market Size, Share, and Growth Forecast 2026 - 2033

Opioid Analgesics Market by Drug Type (Morphine, Oxycodone, Codeine, Fentanyl, Tramadol, Methadone, Others), by Route of Administration (Oral, Injectable, Transdermal, Others), by Application (Cancer Pain, Post-operative Pain, Chronic Pain, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Regional Analysis, 2026 - 2033

ID: PMRREP33953

March 2026

209 Pages

Author : Abhijeet Surwase

Healthcare

Key Industry Highlights:

North America remains the leading region in the opioid analgesics market with about 37% share in 2025, underpinned by high chronic pain prevalence, large cancer and surgical patient populations, and established prescribing practices, even as CDC guidelines and PDMPs have driven more than 40% reductions in dispensing rates since 2012.
Asia Pacific is the fastest-growing region, benefiting from rapid healthcare infrastructure expansion, demographic aging in China with more than 254 million people aged 60+, and regulatory reforms in India and ASEAN that improve medical opioid availability for cancer, post-operative, and chronic pain within structured stewardship frameworks.
Among drug types, Oxycodone dominates with an estimated 36% share in 2025, supported by flexible immediate- and extended-release oral formulations, strong evidence for moderate-to-severe pain control, and uptake of abuse-deterrent versions that mitigate tampering risks while preserving efficacy in oncology, post-operative, and chronic pain indications.
Tramadol stands out as the fastest-growing drug segment, particularly in Europe and Asia Pacific, where its dual mechanism and relatively lower scheduling make it attractive for stepwise pain management, offering a bridge between non-opioid therapies and strong opioids in both chronic musculoskeletal and cancer-related pain.
Key market opportunities center on abuse-deterrent formulations, advanced delivery systems such as transdermal and transmucosal products, and expansion into emerging markets where under-treatment of pain remains substantial, enabling manufacturers with robust compliance, education programs, and diversified portfolios to capture growth while aligning with evolving regulatory and public health expectations.

Key Insights	Details
Opioid Analgesics Market Size (2026E)	US$ 45.1 billion
Market Value Forecast (2033F)	US$ 62.2 billion
Projected Growth CAGR (2026-2033)	4.7%
Historical Market Growth (2020-2025)	4.2%

Get Your CustomizationGet Your Customization

Market Dynamics

Drivers - Rising Chronic Pain Burden and Cancer-Related Pain Management Needs

Escalating chronic pain prevalence and growing cancer incidence are central drivers of the opioid analgesics market. The National Institute on Drug Abuse (NIDA) and CDC estimate that tens of millions of adults in the United States live with chronic pain, with more than 50 million reporting pain on most days, creating sustained demand for potent analgesics when non-opioid measures fail. In oncology, multiple studies show that over 25% of cancer patients experience moderate-to-severe pain, and persistent opioid use develops in roughly 10% of patients after cancer surgery, underscoring opioids’ continued role in palliative and supportive care. In Europe, a large multinational DARWIN EU cohort study found that approximately 1 in 10 adults aged 50+ received at least one opioid prescription in 2019, highlighting widespread clinical reliance for chronic and cancer-related pain. As populations age in North America, Europe, and the Asia Pacific, and cancer prevalence rises, clinically appropriate opioid use in oncology, palliative care, and advanced chronic pain drives stable baseline demand despite tighter controls.

High Surgical Volumes and Post-operative Pain Management Requirements

Global growth in surgical procedures provides another strong underpinning for opioid analgesics consumption. In the United States, more than 50 million inpatient surgical procedures are performed annually, and evidence shows that over 80% of surgical patients receive opioid analgesics perioperatively to manage acute pain. Research published in JAMA Network Open and other journals indicates that 6–10% of previously opioid-naïve patients continue opioid use beyond 90 days after major surgery, demonstrating the significant exposure generated by perioperative care. Similar trends are seen in large European healthcare systems, where opioids are routinely integrated into multimodal post-operative regimens for orthopedic, abdominal, and cardiovascular procedures. In Asia Pacific, rising elective surgery volumes in China and India, driven by expanding hospital infrastructure and insurance coverage, are increasing reliance on short-acting opioids such as morphine, fentanyl, and oxycodone for acute pain control. Even as guidelines from CDC, WHO, and professional societies advocate for the shortest effective duration and the lowest effective dose, the high base of surgical activity ensures ongoing demand from hospital and ambulatory surgery center settings.

Restraints - Stringent Regulatory Controls and Prescription Monitoring Programs

Intensifying regulatory oversight significantly constrains the opioid analgesics market growth, particularly in developed economies. The CDC’s original 2016 opioid prescribing guideline and its updated 2022 version, alongside state-level prescription drug monitoring programs (PDMPs), have led to substantial reductions in high-dose and long-duration prescribing in the United States. CDC dispensing data show that opioid prescribing rates have fallen by more than 40% since their peak in 2012, with more stringent thresholds for daily morphine milligram equivalents and early refill limits. In Europe, regulatory agencies and payers have tightened reimbursement criteria and monitoring, with UK primary care data indicating more than 50% reduction in new opioid prescribing episodes over the past decade, even though overall prevalence in older adults remains considerable. These interventions, while critical for curbing misuse, also reduce total prescription volume, especially in chronic non-cancer pain, thereby moderating market expansion.

Opioid Crisis Awareness and Shift Toward Non-Opioid Alternatives

Public health focus on the opioid crisis has reshaped prescriber and patient attitudes, limiting opioid growth in several indications. According to the WHO, opioids are responsible for the majority of drug-related deaths worldwide, with an estimated 128,000 deaths due to opioid overdose in 2021. In the United States, total drug overdose deaths reached roughly 114,000 in 2023, driven predominantly by synthetic opioids such as illicit fentanyl, fueling prescriber caution and regulatory scrutiny. The U.S. Drug Enforcement Administration (DEA) and state authorities have launched initiatives such as the Fentanyl Free America campaign and tightened controls on dispensing and distribution. In parallel, investment in non-opioid analgesics, including sodium channel (NaV1.8) inhibitors, anti-nerve growth factor antibodies, and neuromodulation approaches, offers alternative pain management options, particularly for chronic musculoskeletal and neuropathic pain. This clinical and societal pivot away from opioids in many chronic pain scenarios acts as a drag on market growth, especially for long-acting formulations.

Opportunities - Abuse-Deterrent Formulations (ADFs) and Advanced Delivery Systems

The development and adoption of abuse-deterrent formulations create a key opportunity segment within the opioid analgesics market. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have encouraged the transition from easily manipulated oral opioids to ADFs designed to resist crushing, dissolving, or injecting, while still delivering effective analgesia when taken as prescribed. Reformulated extended-release oxycodone products, such as abuse-deterrent versions of OxyContin, incorporate physical and chemical barriers that significantly reduce abuse via snorting or injection compared with older formulations. At the same time, transdermal systems (for example, fentanyl patches) and transmucosal formulations (sublingual or buccal tablets and films) deliver steady-state analgesia for cancer and severe chronic pain, improving adherence and reducing peak-related adverse effects. As payers and regulators increasingly favor ADF labeling and risk evaluation and mitigation strategy (REMS) programs, manufacturers capable of demonstrating real-world abuse reduction while maintaining pain control can capture premium pricing and defend market share even in a constrained prescribing environment.

Emerging Markets Expansion and Improving Access to Pain Management in the Asia Pacific

Rapidly developing healthcare systems in the Asia Pacific offer substantial growth potential, particularly where historical access to opioid analgesics has been limited. WHO and palliative care organizations have long highlighted under-treatment of moderate-to-severe pain in low- and middle-income countries, including large parts of Asia, due to regulatory, supply chain, and affordability barriers. As countries such as China, India, and members of the Association of Southeast Asian Nations (ASEAN) expand health insurance coverage and invest in oncology and surgical capacity, demand for strong opioids such as morphine, oxycodone, and fentanyl, as well as weaker opioids like tramadol, is rising. For example, China had approximately 254 million people aged 60 years or older in 2019, a figure expected to grow substantially by 2035, creating a large pool of patients with cancer, osteoarthritis, and other painful chronic diseases. In India, a large unmet need in palliative care and post-operative pain control is prompting regulatory reforms to improve medical opioid availability while maintaining controls on diversion. Manufacturers that can supply high-quality, cost-effective oral and injectable opioids, along with training and stewardship programs, are well-positioned to benefit from these structural shifts.

Category-wise Analysis

Drug Type Insights

Within the opioid analgesics market, Oxycodone is the leading drug type, accounting for approximately 36% of global market share in 2025. As a semi-synthetic mu-opioid receptor agonist, oxycodone offers flexible oral formulations in both immediate-release and extended-release forms, making it suitable for acute post-operative pain, chronic back pain, and cancer-related pain. Prescription data from the CDC and analyses of U.S. outpatient prescribing patterns consistently rank oxycodone among the top-dispensed opioids, alongside hydrocodone and morphine, particularly for moderate-to-severe pain in ambulatory settings. Abuse-deterrent formulations have helped sustain oxycodone’s role despite policy headwinds, as reformulated brands and generics reduce attractiveness for tampering and non-medical use. Clinical studies suggest that oxycodone can provide comparable or superior analgesia to morphine for some surgical and cancer pain indications, with a safety profile familiar to prescribers, further reinforcing its dominance. Tramadol is emerging as the fastest-growing opioid drug type, particularly in markets emphasizing stepwise pain management, due to its dual mechanism of action (weak mu agonism plus serotonin–norepinephrine reuptake inhibition) and relatively lower scheduling in many jurisdictions.

Route of Administration Insights

By route of administration, Oral opioids represent the leading segment, estimated to hold a market share of around 60–65% in 2025, reflecting the central role of tablets and capsules in both chronic and acute pain management. In community and primary care settings, the vast majority of opioid prescriptions are written for oral dosage forms such as immediate-release oxycodone, hydrocodone, and codeine, owing to their convenience, predictable pharmacokinetics, and suitability for outpatient use. The American Medical Association (AMA) and CDC prescribing data show that shifts in opioid use over the last decade have primarily affected oral agents, but they still constitute the bulk of dispensed opioid prescriptions. Injectable opioids, including intravenous morphine and fentanyl, dominate in emergency departments, intensive care units, and operating rooms, where rapid onset and titration are critical, making this the fastest-growing route in hospital settings as surgical procedures expand globally. Transdermal patches, especially fentanyl systems, hold a strong niche in long-term management of cancer pain and severe chronic pain in patients who cannot tolerate oral medications, supported by oncology and palliative care guidelines in Europe and North America.

Distribution Channel Insights

By distribution channel, retail pharmacies are the leading segment, estimated to account for roughly 50–55% of global opioid analgesic sales in 2025, reflecting the dominance of outpatient prescribing. In the United States, most prescriptions for oral opioids are dispensed through community pharmacy networks, which are also key touchpoints for prescription drug monitoring program (PDMP) surveillance and patient counseling. Retail channels in Europe similarly handle the majority of chronic pain and post-operative take-home prescriptions, under tight reimbursement and monitoring controls. Hospital Pharmacies hold a substantial share, particularly for injectable and transdermal opioids used in inpatient, intensive care, and oncology units, and they remain crucial in formulary decisions and stewardship initiatives. Online Pharmacies constitute the fastest-growing distribution channel, especially in North America and parts of Europe and Asia Pacific, where legitimate e-pharmacy platforms have expanded under stricter verification and e-prescribing frameworks. Regulatory bodies have simultaneously targeted illicit online sales, distinguishing licensed digital pharmacies from rogue websites as part of broader opioid crisis responses.

Request Free sampleRequest Free sample

Regional Insights

North America Opioid Analgesics Market Trends and Insights

North America remains the leading region in the opioid analgesics market due to the high prevalence of chronic pain conditions, a well-established healthcare infrastructure, and strong access to prescription pain management therapies. The region has a large population suffering from cancer pain, post-surgical pain, arthritis, and musculoskeletal disorders, which increases the demand for effective opioid medications in hospitals and pain management clinics. In addition, the presence of major pharmaceutical manufacturers, extensive research activities, and ongoing product innovation support market growth. Regulatory agencies have also implemented stricter monitoring systems and prescription guidelines to reduce opioid misuse while ensuring availability for patients with severe pain. The increasing number of surgical procedures and the rising geriatric population further contribute to the demand for opioid-based analgesics. Moreover, improved palliative care services and better awareness of pain management practices continue to drive the adoption of opioid analgesics across healthcare facilities throughout North America.

Asia Pacific Opioid Analgesics Market Trends and Insights

Asia Pacific is the fastest-growing regional market for opioid analgesics, driven by large populations, expanding healthcare infrastructure, and increasing recognition of pain management as a human right. In China, demographic aging is dramatic, with approximately 254 million people aged 60 years or older as of 2019, expected to rise significantly by 2035, contributing to higher prevalence of cancer, osteoarthritis, and other chronic pain conditions requiring stronger analgesia. In India, the number of people living with chronic pain is estimated in the tens of millions, yet access to strong opioids remains uneven, prompting regulatory reforms to simplify medical use of morphine and other essential opioids under the amended Narcotic Drugs and Psychotropic Substances (NDPS) Act.

Manufacturing cost advantages in India and parts of China have supported a robust generics industry, supplying oral morphine, oxycodone, tramadol, and combination products to domestic and export markets. At the same time, some ASEAN countries are investing in palliative care networks and cancer centers, increasing demand for injectable and transdermal formulations suitable for hospital and hospice settings. International organizations and local professional societies are working to balance concerns about misuse with the imperative to treat severe pain, leading to gradual relaxation of overly restrictive procurement rules while retaining stringent controls on diversion. As awareness of multimodal pain management grows and insurance coverage expands, the Asia Pacific is expected to post the highest compound annual growth rate among all regions for opioid analgesics through 2033, particularly in segments such as tramadol and hospital-based injectable opioids.

Competitive Landscape

The opioid analgesics market is highly competitive, with numerous pharmaceutical manufacturers competing through product innovation, pricing strategies, and regulatory compliance. Companies focus on developing improved formulations such as extended-release and abuse-deterrent opioids to enhance safety and reduce misuse risks. Increasing investments in research and development are aimed at improving drug efficacy, delivery systems, and controlled dosing mechanisms. Strategic collaborations, mergers, and partnerships are also common as firms expand their product portfolios and geographic presence.

Key Market Developments

In August 2025, Chemomouthpiece, LLC announced the results of a pivotal multi-center randomized controlled clinical trial evaluating its FDA-cleared Chemo Mouthpiece®, an intraoral cryotherapy device designed to reduce chemotherapy-induced oral mucositis.
In January 2026, Vivozon Pharmaceutical launched a 20 mL small-pack version of its non-opioid injectable analgesic Onaprazoo in South Korea, aiming to expand pain management options in medical settings. The drug is designed to treat moderate to severe acute pain, particularly after surgical procedures.

Opioid Analgesics Market Research Segmentation

By Drug Type

Morphine
Oxycodone
Codeine
Fentanyl
Tramadol
Methadone
Others

By Route of Administration

Oral
Injectable
Transdermal
Others

By Application

Cancer Pain
Post-operative Pain
Chronic Pain
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
East Asia
South Asi/a & Oceania
Latin America
Middle East & Africa

Companies Covered in Opioid Analgesics Market

Pfizer Inc.
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Mallinckrodt Pharmaceuticals
Endo International plc
AbbVie Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Mylan N.V.
Bayer AG

Frequently Asked Questions

The global Opioid Analgesics market size is projected to reach approximately US$ 45.1 billion in 2026, and is expected to further expand to around US$ 62.2 billion by 2033, reflecting a forecast compound annual growth rate of about 4.7% over 2026–2033.

Key demand drivers include the high and persistent burden of chronic pain affecting more than 50 million adults in the United States, substantial cancer-related pain requiring strong opioids in over 25% of oncology patients, and growing global surgical volumes exceeding 50 million inpatient procedures annually in the U.S. alone, all of which sustain medically appropriate opioid use despite stewardship measures.

North America is the leading regional market, accounting for about 37% of global opioid analgesics revenues in 2025, underpinned by high chronic pain prevalence, large oncology and surgical caseloads, and historical prescribing patterns, even as CDC guidelines, PDMPs, and broader policy interventions have substantially reduced high-risk and long-duration prescribing.

A major growth opportunity lies in the development and uptake of abuse-deterrent formulations and advanced delivery systems, alongside expansion into under-served Asia Pacific markets where demographic aging, rising cancer incidence, and improving access to palliative and post-operative care are increasing demand for safe, well-regulated opioid therapies.

Prominent market participants include Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Purdue Pharma L.P., Mallinckrodt Pharmaceuticals, Endo International plc, AbbVie Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Mylan N.V./Viatris Inc., and Bayer AG, complemented by regional generic manufacturers such as Dr. Reddy’s Laboratories Ltd. and Epic Pharma LLC.

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis Units	Value: US$ Mn/Bn
Geographical Coverage	North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa
Segmental Coverage	Drug Type Route of Administration Application Distribution Channel Region
Competitive Analysis	Pfizer Inc. Johnson & Johnson Teva Pharmaceutical Industries Ltd. Purdue Pharma L.P. Mallinckrodt Pharmaceuticals Endo International plc AbbVie Inc. Sanofi S.A. Sun Pharmaceutical Industries Ltd. Hikma Pharmaceuticals PLC Mylan N.V. Bayer AG
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Key Insights

Details

Opioid Analgesics Market Size (2026E)

US$ 45.1 billion

Market Value Forecast (2033F)

US$ 62.2 billion

Projected Growth CAGR (2026-2033)

4.7%

Historical Market Growth (2020-2025)

4.2%

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis Units	Value: US$ Mn/Bn
Geographical Coverage	North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa
Segmental Coverage	Drug Type Route of Administration Application Distribution Channel Region
Competitive Analysis	Pfizer Inc. Johnson & Johnson Teva Pharmaceutical Industries Ltd. Purdue Pharma L.P. Mallinckrodt Pharmaceuticals Endo International plc AbbVie Inc. Sanofi S.A. Sun Pharmaceutical Industries Ltd. Hikma Pharmaceuticals PLC Mylan N.V. Bayer AG
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools

Executive Summary
1. Global Opioid Analgesics Market Snapshot 2026 and 2033
2. Market Opportunity Assessment, 2026-2033, US$ Bn
3. Key Market Trends
4. Industry Developments and Key Market Events
5. Demand Side and Supply Side Analysis
6. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definitions
2. Market Dynamics
  1. Driver
  2. Restraint
  3. Opportunities
  4. Trends
3. Macro-Economic Factors
  1. Global GDP Outlook
  2. Global Healthcare Expenditure
4. Forecast Factors – Relevance and Impact
5. COVID-19 Impact Assessment
Value Added Insights
1. Value Chain analysis
2. Key Market Players
3. Drug Adoption Analysis
4. Key Promotional Strategies by key players
5. PESTLE Analysis
6. Porter's Five Forces Analysis
7. Regulatory and Technology Landscape
Global Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Global Opioid Analgesics Market Outlook: Drug Type
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Drug Type, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
    1. Morphine
    2. Oxycodone
    3. Codeine
    4. Fentanyl
    5. Tramadol
    6. Methadone
    7. Others
  4. Market Attractiveness Analysis: Drug Type
3. Global Opioid Analgesics Market Outlook: Route of Administration
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Route of Administration, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
    1. Oral
    2. Injectable
    3. Transdermal
    4. Others
  4. Market Attractiveness Analysis: Route of Administration
4. Global Opioid Analgesics Market Outlook: Application
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Application, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Application, 2026-2033
    1. Cancer Pain
    2. Post-operative Pain
    3. Chronic Pain
    4. Others
  4. Market Attractiveness Analysis: Application
5. Global Opioid Analgesics Market Outlook: Distribution Channel
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Distribution Channel, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  4. Market Attractiveness Analysis: Distribution Channel
Global Opioid Analgesics Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis by Region, 2020-2025
3. Current Market Size (US$ Bn) Forecast, by Region, 2026-2033
  1. North America
  2. Europe
  3. East Asia
  4. South Asia & Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. North America Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. U.S.
  2. Canada
3. North America Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. North America Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. North America Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. North America Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Europe Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Europe Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. Germany
  2. Italy
  3. France
  4. U.K.
  5. Spain
  6. Russia
  7. Rest of Europe
3. Europe Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. Europe Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. Europe Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. Europe Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
East Asia Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. East Asia Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. China
  2. Japan
  3. South Korea
3. East Asia Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. East Asia Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. East Asia Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. East Asia Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
South Asia & Oceania Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of SAO
3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. South Asia & Oceania Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Latin America Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Latin America Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. Brazil
  2. Mexico
  3. Rest of LATAM
3. Latin America Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. Latin America Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. Latin America Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. Latin America Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Middle East & Africa Opioid Analgesics Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. GCC Countries
  2. South Africa
  3. Northern Africa
  4. Rest of MEA
3. Middle East & Africa Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Morphine
  2. Oxycodone
  3. Codeine
  4. Fentanyl
  5. Tramadol
  6. Methadone
  7. Others
4. Middle East & Africa Market Size (US$ Bn) Forecast, by Route of Administration, 2026-2033
  1. Oral
  2. Injectable
  3. Transdermal
  4. Others
5. Middle East & Africa Market Size (US$ Bn) Forecast, by Application, 2026-2033
  1. Cancer Pain
  2. Post-operative Pain
  3. Chronic Pain
  4. Others
6. Middle East & Africa Market Size (US$ Bn) Forecast, by Distribution Channel, 2026-2033
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping
  2. Competition Dashboard
3. Company Profiles
  1. Pfizer Inc.
    1. Company Overview
    2. Product Portfolio/Offerings
    3. Key Financials
    4. SWOT Analysis
    5. Company Strategy and Key Developments
  2. Johnson & Johnson
  3. Teva Pharmaceutical Industries Ltd.
  4. Purdue Pharma L.P.
  5. Mallinckrodt Pharmaceuticals
  6. Endo International plc
  7. AbbVie Inc.
  8. Sanofi S.A.
  9. Sun Pharmaceutical Industries Ltd.
  10. Hikma Pharmaceuticals PLC
  11. Mylan N.V.
  12. Bayer AG
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Opioid Analgesics Market Size, Share, and Growth Forecast 2026 - 2033